Background: Post Kala-azar Dermal Leishmaniasis (PKDL) is a sequela of Visceral Leishmaniasis (VL) and suggested as reservoirs of parasite. Currently, Miltefosine (MF), Amphotericin B Deoxycholate (ABD) and Liposomal Amphotericin B (LAmB) are recommended by World health organization (WHO) as treatment options for PKDL. But single MF or LAmB often causes incomplete cure specially cases with extensive lesion. To overcome this problem here we describe four cases of PKDL who had widespread nodular and macular lesions and were treated with two cycles of LAmB doses with 20 mg/kg body weight divided into 4 equal doses and administered every alternate day. Methods & Materials: Patients admitted to the Surya kanta kala-azar research centre (SKKRC) with extensive nodular or mixed lesion were considered to treat with LAmB. Hospital physician collected patients’ history and performed physical examination. Suspected cases were confirmed by microscopic examination of slit skin smear. At first, LAmB treatment was initiated at the dose of 20 mg/kg into four divided doses every alternate day. Before starting treatment all haematological and biochemical markers were checked. Second cycle was initiated for those who displayed marked improvement but not complete recovery. Finally, a follow up physical and microscopic examination was also done to evaluate the treatment outcome. Results: Of them, two had previous VL history and two had no previous VL history at all. The lesions started from chin with macular type, later distributed to other parts of the body with both macular and nodular type. The lesions were non-itching, touch sensitive and rk 39 strip test was positive. All of them were confirmed through microscopic examination of slit skin smear. Their haematological and biochemical markers were within normal limit. After first cycle, all of them showed initial progress and after second cycle all of them attained complete cure. Fever with shivering was the only documented adverse event during treatment and was managed by paracetamol. Conclusion: The cases highlighted in this report explore the success of utilising extended LAmB dose schedule for treating a patient with widespread lesions.The triumph of this alternate treatment schedule for PKDL needs to be supported with clinical trials that evaluate its efficacy and safety.